Novartis AG

NVS · SWISS

$151.12−$5.15 (−3.30%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $156.27

Latest news

NewsOct 23, 12:44 PM ET
Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis
NewsOct 23, 7:53 AM ET
Novartis Announces Its Data From Phase III NATALEE Study Demonstrates Kisqali Eliminates Risk Of Death By ~20% In Patients With Stage II And III HR+/Her2- Early Breast Cancer
Press releaseOct 15, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Press releaseOct 13, 5:34 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Press releaseOct 8, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NewsOct 7, 2:28 PM ETVandana Singh
FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives
NewsOct 7, 11:54 AM ET
Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism
Press releaseOct 1, 10:00 AM ETPRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
Press releaseSep 29, 5:39 PM ETGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS
NewsSep 22, 12:25 PM ETVandana Singh
Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease
NewsSep 17, 12:47 PM ETVandana Singh
Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform
NewsSep 16, 11:39 AM ET
'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg
NewsSep 11, 9:28 AM ETVandana Singh
Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks
Press releaseSep 10, 2:12 PM ETGlobe Newswire
Big Pharma Setbacks Create a New Wave of Rebound Plays
Press releaseSep 10, 8:30 AM ETGlobe Newswire
Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market
NewsSep 10, 6:06 AM ETAnusuya Lahiri
Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off
Press releaseSep 9, 1:24 PM ETPRNewswire
Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)
NewsSep 8, 1:47 PM ETVandana Singh
A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower
NewsSep 8, 1:40 PM ETVandana Singh
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
NewsSep 8, 1:17 PM ETPiero Cingari
QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000
NewsSep 8, 1:13 PM ETPiero Cingari
S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today
NewsSep 8, 12:50 PM ETVandana Singh
What's Going On With Amgen Stock Tuesday?
NewsSep 8, 12:02 PM ETAvi Kapoor
Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings
NewsSep 8, 10:19 AM ETKaustubh Bagalkote
Why Is Eli Lilly Stock Falling Tuesday?
NewsSep 8, 8:32 AM ETRishabh Mishra
Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)
NewsSep 8, 8:01 AM ETAvi Kapoor
Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
NewsSep 8, 8:01 AM ETVandana Singh
Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners
NewsSep 8, 7:16 AM ET
Market-Moving News for September 8th
NewsSep 8, 3:11 AM ETAvi Kapoor
United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday
NewsSep 7, 12:46 PM ETPiero Cingari
Brent Jumps to $97, German AfD Party Wins Big: Stock Market Today
NewsSep 4, 11:33 AM ETVandana Singh
A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths
NewsSep 1, 9:54 AM ETAvi Kapoor
Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday
NewsAug 3, 12:56 PM ETVandana Singh
FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto
NewsJul 21, 9:45 AM ET
Novartis Q2 2026 Earnings Call Transcript
NewsJul 21, 8:21 AM ETVandana Singh
Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline
NewsJun 24, 12:24 PM ETVandana Singh
Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal
NewsJun 24, 8:41 AM ET
Antares Therapeutics Partners With Novartis To Discover, Develop, Commercialize Small Molecule Therapies To Treat Undruggable Oncology Targets; Antares To Receive $105M Upfront Payment
Press releaseJun 24, 8:30 AM ETGlobe Newswire
The Quest to Repair What Multiple Sclerosis Takes Away
Press releaseFeb 27, 9:00 AM ETGlobe Newswire
Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy
NewsFeb 18, 8:59 AM ETVandana Singh
Itchy Skin Conditions? Novartis' Pivotal Trial Success Shows Potential For Targeted Relief
NewsFeb 17, 12:00 PM ET
A Look Into Novartis Inc's Price Over Earnings

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Novartis Announces Remibrutinib Lowers Annualized Relapse Rate By 35.2%, 31.2% In Phase III REMODEL-1, REMODEL-2 Studies To Treat Relapsing Multiple Sclerosis

Novartis Announces Its Data From Phase III NATALEE Study Demonstrates Kisqali Eliminates Risk Of Death By ~20% In Patients With Stage II And III HR+/Her2- Early Breast Cancer

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

FDA Greenslights Novartis's Rhapsido as First Treatment for Chronic Friction Hives

Novartis Receives FDA Approval For Rhapsido To Treat Symptomatic Dermographism

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

Celldex Prepares For 2027 FDA Submission for Chronic Skin Disease

Novartis Halts Experimental ALS Drug Trial but Acquires Brain Delivery Platform

'Novartis Experimental Drug for ALS Fails in Another Pipeline Hit' - Bloomberg

Top Investor Urges Novartis for Stronger Acquisition Oversight After M&A and Trial Setbacks

Big Pharma Setbacks Create a New Wave of Rebound Plays

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

Nvidia, FAA Join Palantir’s AI Expansion as Cyber Push Takes Off

Novartis Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Novartis (NVS)

A Rivals Clinical Stumble Sends Sarepta Therapeutics Stock Lower

Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling

QUICK SPARK: Amgen Stock Eyes Worst Day Since October 2000

S&P 500, Nasdaq Slip as $98 Brent Reignites Inflation Fears: Stock Market Today

What's Going On With Amgen Stock Tuesday?

Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings

Why Is Eli Lilly Stock Falling Tuesday?

Stock Market Today: S&P 500, Dow, Nasdaq 100 Futures Fall as Oil Tops $99 Despite Trump’s Price Drop Prediction— ASML, NVS, CASY in Focus (UPDATED)

Novartis, Ionis Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session

Novartis Stock Drops as Trial Failures Ripple Across Biotech Partners

Market-Moving News for September 8th

United Natural Foods, ABM Industries and 3 Stocks to Watch Heading Into Tuesday

Brent Jumps to $97, German AfD Party Wins Big: Stock Market Today

A Wall Street Analyst Spotted the Trial Freeze—Then Came News of Three Deaths

Yext Posts Upbeat Q2 Earnings, Joins Fervo Energy, MiniMed Group And Other Big Stocks Moving Higher On Tuesday

FDA Approval Nearly Doubles Eligible Patient Pool For Novartis' Pluvicto

Novartis Q2 2026 Earnings Call Transcript

Novartis Silences Generic Fears With Blowout Quarter, Packed Pipeline

Novartis, Antares Partner To Pursue Undruggable Cancer Targets In $1.9 Billion Deal

Antares Therapeutics Partners With Novartis To Discover, Develop, Commercialize Small Molecule Therapies To Treat Undruggable Oncology Targets; Antares To Receive $105M Upfront Payment

The Quest to Repair What Multiple Sclerosis Takes Away

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

Itchy Skin Conditions? Novartis' Pivotal Trial Success Shows Potential For Targeted Relief

A Look Into Novartis Inc's Price Over Earnings